Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis

Risk Factors for Developing Glaucoma Among Patients With Uveitis

“…It has been proven that managing uveitis-related glaucoma is quite difficult, and that only 24% of patients can be successfully treated by topical medications alone. 12,21,22 Early detection and intervention of ocular hypertension tends to be the most effective way to reduce the vision loss in uveitis patients. 23 Several factors have been reported to be associated with the incidence of glaucoma in uveitis patients.…”

Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy

“…The probability of the success of trabeculectomy in vitrectomized eyes 1 year after surgery for all the patients in this study was 55.1 %. This result is relatively poor compared with results of filtration surgery for uveitic glaucoma or NVG either with or without vitrectomy [2,3]. We calculated the probability of success for trabeculectomy in eyes with NVG by using the same methods of analysis as those used in comparable reports.…”

“…Some of these vitreoretinal diseases can cause secondary glaucoma after vitrectomy, which requires filtering surgery to lower the intraocular pressure (IOP). Trabeculectomy with mitomycin C (MMC) is a widely performed filtering surgery used in these cases [1][2][3]. Because the success of trabeculectomy depends mainly on bleb survival, conjunctival scarring after ocular surgery is a major factor in surgical failure of trabeculectomy [4].…”

Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease

“…Yalvac and colleagues reported cataract formation as the most common complication after trabeculectomy with MMC in Behcet disease. [12][13][14][15] The chronicity of the disease and the use of steroids are mostly the reason for such high incidence of cataract after trabeculectomy. Such incidence could probably be reduced by using immunomodulatory therapy to achieve better control of inflammation and reduce vision-threatening complications occurring in the chronic, recurrent phase of VKH.…”